
Maria Lopes-Virella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/273663/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial. Stroke, 2020, 51, 2960-2971.	2.0	19
2	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes, 2020, 69, 2440-2445.	0.6	2
3	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2020, 69, 1000-1010.	0.6	106
4	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2020, 43, 867-874.	8.6	61
5	Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes, 2019, 68, 1853-1860.	0.6	15
6	Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages. Clinical Immunology, 2018, 187, 1-9.	3.2	13
7	Haptoglobin 2–2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Journal of Diabetes and Its Complications, 2016, 30, 1577-1584.	2.3	20
8	Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes, 2016, 65, 498-502.	0.6	12